- Ovarian cancer: up to 80%5
- Pancreatic cancer: up to 80%6
- Liver cancer: up to 70%7
- Bladder cancer: up to 70%8
ARTICLE
Decoding medical inflation: the truth behind rising costs, and planning ahead for peace of mind
8-min read
Updated on 2026-7-3
Author: AIA Content Editorial Team
Three forces driving medical inflation
1. Ageing population | Longer lives, more chronic disease
2. Long-term treatment becomes the norm | High cancer incidence and recurrence risk
3. Advances in medical technology | New hope that also lifts costs
Take the new CAR-T cell therapy: treating cancer with it can cost as much as HK$2 million to HK$3 million9. In cardiac care, the new generation dissolvable stent — a bioresorbable vascular scaffold (BVS) used in angioplasty — costs around HK$30,000, while the procedure itself can run from HK$100,000 to HK$300,000 at a private hospital10.
Plan ahead — and lock in your protection while the timing is right
- Adjustments to your premium
- Restrictions on the coverage
- In some cases, application may be declined
Medical Inflation & Health Trends FAQs
- Higher premiums: with greater health risk, you may need to pay an extra premium loading
- Restricted cover: certain pre-existing conditions or related illnesses may be listed as exclusions
- Possible decline: your health and medical history may mean cover cannot be granted
- The total medical claims amount and the customers with claims paid are based on approved-case data for both individual and group medical claims.
- Individual medical claims data excludes other general outpatient plans and hospital cash plans; group medical claims data covers inpatient, outpatient and hospital cash benefits.
- The above data only includes approved cases and is calculated by coverage category.
- "The past seven years" refers to data from 2019 to 2025. The increase in medical inflation is calculated on a compound annual basis with reference to data from the WTW Global Medical Trends Survey, 2021 to 2026.
- The Hong Kong Federation of Insurers — The Determinants of Post-Pandemic Medical Inflation: An Analysis of Private Insurance Claims Data in Hong Kong (2026)
- Census and Statistics Department, HKSAR Government — Statistics and You (November 2025)
- Hong Kong Cancer Registry — Overview of Hong Kong Cancer Statistics of 2022 (2024)
- MyOvarianCancerTeam website — Recurrent Ovarian Cancer Explained (2025)
- World Journal of Surgical Oncology website — Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection (2023)
- MDPI website — Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review (2024)
- BMC Cancer website — Clinical determinants of recurrence in pTa bladder cancer following transurethral resection of bladder tumor (2022)
- UrbanLife — HKU and Hong Kong Science Park jointly set up a cell therapy laboratory to research CAR-T cell therapy for patients with blood cancer and cardiovascular disease (2023)
- Hong Kong Economic Journal — Angioplasty costs: public vs private hospital fees; recurrence rate below 5%! A detailed guide to the angioplasty procedure (2025)
- According to the YouGov Hong Kong BrandIndex (2016–2025), compiled by global research and data analytics firm YouGov, AIA has been the Top Insurance Brand in Brand Consideration and Most Likely to Purchase in Hong Kong for 10 consecutive years.
- Source: 2025 AIA Medical Claims Data